Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nerisopam SCHEMBL8349837 | 1.00 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6293666 | 0.92 | ALDH1A1 (0.60) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6290864 | 0.92 | ALDH1A1 (0.60) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7615727 | 0.90 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL15974264 | 0.86 | CHEK1 (0.51) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7439770 | 0.86 | MAPT (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6420733 | 0.86 | MEN1 (0.52) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7410880 | 0.86 | PDGFRB (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL10887682 | 0.86 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL10884494 | 0.86 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | claimed |
| EP-2459227-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | claimed |
| CN-1681512-B | Use of 2, 3-benzodiazepines in the treatment of basal ganglia-related movement disorders | MOTAC NEUROSCIENCE LTD | 2011-11-09 | — | — | CN | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| WO-2011012722-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| CN-1681512-A | Treatment of basal ganglia-related movement disorders with 2, 3-benzodiazepines | MOTAC NEUROSCIENCE LTD (GB) | 2005-10-12 | — | — | CN | claimed |
| EP-1545546-A1 | TREATMENT OF BASAL GANGLIA-RELATED MOVEMENT DISORDERS WITH 2,3-BENZODIAZEPINES | Motac Neuroscience Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | PHARMACIA CORPORATION (US) | 2004-07-29 | — | — | US | claimed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| WO-2004024163-A1 | TREATMENT OF BASAL GANGLIA-RELATED MOVEMENT DISORDERS WITH 2,3-BENZODIAZEPINES | MOTAC NEUROSCIENCE LIMITED (GB) | 2004-03-25 | — | — | WO | claimed |
| WO-2000020005-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN OPIATE ANALGESIC AND A SYNERGIZING SUBSTANCE | EGIS Gyógyszergyár Rt. (HU) | 2000-04-13 | — | — | WO | claimed |
| WO-1999004797-A1 | USE OF 2,3-BENZODIAZEPINE DERIVATIVES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT DISEASES CONNECTED WITH THE ENDOGENOUS OPIOID SYSTEM | EGIS Gyógyszergyár Rt. (HU) | 1999-02-04 | — | — | WO | claimed |
| US-4614740-A | NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR (HU) | 1986-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | CYP1A2 1143/4885CYP3A4 750/4885CYP2C9 383/4885 |
| US-20040147581-A1 | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy | HTR2A, HTR1A, TPH2 | CYP1A2 161/4885CYP3A4 839/4885CYP2C9 867/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP1A2 90/4885CYP3A4 867/4885CYP2C9 972/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP1A2 90/4885CYP3A4 867/4885CYP2C9 972/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP1A2 90/4885CYP3A4 867/4885CYP2C9 972/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CYP1A2 90/4885CYP3A4 867/4885CYP2C9 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.